Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer · Small-cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 110 (planned)
- Started
- Aug 5, 2024
- Main results expected
- Jun 2027
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs
Measured over: up to 100 days after the last dose of treatment
Occurrence of dose interruption, reduction, and discontinuation of study treatment due to TEAEs
Measured over: up to 100 days after the last dose of treatment
Objective Response Rate
Measured over: until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
Best percentage change from baseline in the tumor size
Measured over: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
Proportion of participants who have achieved early tumor shrinkage
Measured over: up to 2 months after first dose of treatment
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["statusModule"]}
Trial ID NCT06449209 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC